China News Service, December 20. According to foreign media reports on the 19th, recently, the scientific analysis company Airfinit and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), a scientific analysis company that studies global supply, and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) jointly analyzed data showing that the current global new crown vaccine Most of the products are produced in China with 4.5 billion doses, followed by Europe with nearly 2.3 billion doses.

Data map: Vaccines on the production line of Beijing Kexing Zhongwei Biotechnology Co., Ltd.

Photo by China News Agency reporter Jiang Qiming

  According to reports, Airfinit estimates that since 2021, the global production of new crown vaccines will be approximately 11.15 billion doses.

  Among them, about 4.5 billion doses were produced in China, and nearly 2.3 billion doses were produced in Europe. In addition, India and the United States produced approximately 1.6 billion doses and 950 million doses, respectively.

  The company's analysis believes that by the end of June 2022, the world will continue to produce 8.7 billion doses of existing vaccines.

However, if vaccine manufacturers need to improve the vaccine based on the Omi Keron variant, production will be reduced by approximately 3.7 billion doses.

On September 6th, in the exhibition area of ​​Beijing Shougang Park of the 2021 Service and Trade Fair, Sinopharm China Biotech exhibited the world's first second-generation vaccine against the new crown variant strain.

Photo by China News Agency reporter Jia Tianyong

  The study also pointed out that, at present, there is a huge difference in global vaccine distribution, especially between rich and poor countries.

  According to statistics, currently about 57% of the world’s population have received at least two doses of the vaccine.

However, there is a serious imbalance in the distribution of vaccines.

The World Health Organization points out that there are 41 countries in the world who have received a dose of less than 10% of the population. Most of these countries are in Africa.

  At the same time, the New Coronavirus Vaccine Implementation Plan (Covax) launched by the World Health Organization is providing more vaccines to poor countries.

Data show that as of the end of November, the total number of vaccines available to poor countries reached 784 million doses.

According to Airfinity's estimates, even if all citizens of wealthy countries such as Europe and the United States are vaccinated with booster shots, there will still be a surplus of 1.4 billion vaccine doses in the wealthy countries by March 2021.

Data map: Belgian medical staff are preparing for the new crown vaccination work.

  Cooney, director general of the International Federation of Pharmaceutical Manufacturers Associations, said, "We have failed on the issue of equitable vaccine distribution, and we must do better in 2022."

  Regarding the issue of vaccine patents, McMary Heath, Chairman of the Biotechnology Innovation Organization, said that pharmaceutical manufacturers have established cooperation with more than 300 partners around the world.

  Heath emphasized that patents are very important to encourage innovation in pharmaceutical companies.

She also pointed out that many people in many countries have not been vaccinated. The reason is not that the number of vaccines is too small, but that they have encountered problems when launching the vaccination program on a large scale, including skepticism about vaccination.